Alembic Pharmaceuticals, a Rs.1,850 crore plus pharma major, has posted satisfactory financial performance during the second quarter ended September 2014 and its consolidated net profit moved up by 25.4 per cent to Rs.77.27 crore from Rs.61.64 crore in the corresponding period of last year. Its consolidated net sales improved by 12.4 per cent to Rs.546.25 crore from Rs.485.90 crore. EBDITA went up by 16.7 per cent to Rs.108.40 crore from Rs.92.91 crore.
The company's branded formulations sales in India increased by 17.7 per cent to Rs.275.5 crore from Rs.234.1 crore in the similar quarter of last year. Specialty and acute segments grew by 18 per cent and 17 per cent respectively. Its international generic formulations sales improved by 8.5 per cent to Rs.123.4 crore from Rs.113.7 crore.
Alembic filed one ANDA during the second quarter ended September 2014 and cumulative ANDA filings reached at 65. It also filed 2 DMFs, taking cumulative DMF filings of the company to 68.
For the first half ended September 2014, Alembic's consolidated net sales increased by 14 per cent to Rs.1,045 crore from Rs.916.45 crore and its net profit went up sharply by 31.1 per cent to Rs.141.95 crore from Rs.108.28 crore. EPS worked out to Rs.7.53 as against Rs.5.74 in the last period. EBDITA margins worked out to 19.6 per cent as against 17.9 per cent.